• Explore /
  • Poster
  • / Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.

Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.

Abstract Poster

Authors

null

Rachel Occhiogrosso Abelman

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

Rachel Occhiogrosso Abelman , Laura Spring , Andrzej Niemierko , Elizabeth Abraham , Mary McNeice , Jennifer Goff , Amanda Valenti , Seth Andrew Wander , Steven J. Isakoff , Beverly Moy , Dejan Juric , Neelima Vidula , Adrienne Gropper Waks , Heather Anne Parsons , Leif W. Ellisen , Sara M. Tolaney , Aditya Bardia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT04039230

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 1102)

DOI

10.1200/JCO.2024.42.16_suppl.1102

Abstract #

1102

Poster Bd #

80

Abstract Disclosures

Similar Posters

First Author: Shao Zhimin

First Author: Philippa Corrie

First Author: Alexander Starodub

First Author: Shipra Gandhi